EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cost-Utility analysis of Patient-Led Follow-Up after Rectal Cancer Compared to Standard Follow-Up: A three-year follow-up of the FURCA Randomised Controlled Trial

Bettina Wulff Risør, Nasrin Tayyari, Liza Sopina, Therese Juul, Søren Laurberg, Henriette Vind Thaysen, Ida Hovdenak

Journal of Cancer Survivorship · 2026-10 · 20 (S2) · 1467-1478

DOI: 10.1007/s11764-026-01976-9 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cancer Survivorship, online erschienen am 29.01.2026. Verfasst von Bettina Wulff Risør und 6 weiteren Autor:innen. Beteiligte Einrichtung: DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, Aarhus N, 8200, Denmark. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Rectal Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aarhus University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Rectal cancer survivors are at risk of late adverse effects that impair quality of life. This study evaluates the cost-utility of a patient-led follow-up programme introduced in the Danish FURCA randomised controlled trial (RCT), aimed at improving patient outcomes and optimising healthcare resource use compared to standard hospital-based follow-up.

Methods

The cost-utility analysis was performed from a societal perspective over a 3-year horizon, incorporating healthcare costs, prescription drug use, productivity losses, all derived from Danish register data, and quality-adjusted life years (QALYs) derived from RCT-collected EQ-5D-5L data. Incremental cost-effectiveness was assessed using regression models and non-parametric bootstrapping, with subgroup and sensitivity analyses exploring heterogeneity in outcomes.

Results

A total of 336 patients were randomised to intervention and control groups. Over 3 years, mean healthcare costs were €40,208 for the intervention group and €41,190 for the control group (difference −€980; 95% CI −€7120 to €5159). Mean QALYs were 2.24 and 2.20, respectively (difference 0.028; 95% CI −0.106 to 0.163). The incremental cost-effectiveness ratio was −€35,048 per QALY gained, indicating dominance. Scatterplots of bootstrapped incremental cost-effectiveness ratios (ICERs) revealed iterations in all four quadrants, reflecting substantial uncertainty in both costs and effects. The probability of cost-effectiveness at a €30,000 threshold was below 70%.

Conclusions

Patient-led follow-up resulted in comparable QALYs and costs relative to standard hospital-based follow-up. The probability of cost-effectiveness at a conventional willingness-to-pay threshold reached up to 70%. Implications for cancer survivors Patient-led models may enable tailored delivery of specialist care to patients with greatest need, alongside balanced resource utilisation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisRectal NeoplasmsAgedFemaleHumansMaleMiddle AgedDenmarkFollow-Up StudiesHealth Care CostsQuality of LifeQuality-Adjusted Life Years

Stichwörter der Autor:innen

Cost-utility analysesFollow-up careHealth economicsPatient-ledRandomised controlled trialRectal cancerSurvivorship

Autor:innen und Institutionen

  • DEFACTUM, Central Denmark Region, Olof Palmes Allé 15, Aarhus N, 8200, Denmark.
  • Danish Center for Health Economics, University of Southern Denmark, Campusvej 55, Odense C, 5230, Denmark.
  • Department of Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark.
  • Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, Aarhus N, 8200, Denmark.
  • Department of Surgery, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus N, 8200, Denmark. idajak@rm.dk.

Förderung

  • Aarhus University Hospital

Zitieren

APA

Risør, B. W., Tayyari, N., Sopina, L., Juul, T., Laurberg, S., Thaysen, H. V., & Hovdenak, I. (2026). Cost-Utility analysis of Patient-Led Follow-Up after Rectal Cancer Compared to Standard Follow-Up: A three-year follow-up of the FURCA Randomised Controlled Trial. Journal of Cancer Survivorship, 20(S2), 1467-1478. https://doi.org/10.1007/s11764-026-01976-9

Vancouver

Risør BW, Tayyari N, Sopina L, Juul T, Laurberg S, Thaysen HV, et al. Cost-Utility analysis of Patient-Led Follow-Up after Rectal Cancer Compared to Standard Follow-Up: A three-year follow-up of the FURCA Randomised Controlled Trial. Journal of Cancer Survivorship. 2026;20(S2):1467-1478. doi:10.1007/s11764-026-01976-9

BibTeX
@article{Risr2026,
  author = {Risør, Bettina Wulff and Tayyari, Nasrin and Sopina, Liza and Juul, Therese and Laurberg, Søren and Thaysen, Henriette Vind and Hovdenak, Ida},
  title = {Cost-Utility analysis of Patient-Led Follow-Up after Rectal Cancer Compared to Standard Follow-Up: A three-year follow-up of the FURCA Randomised Controlled Trial},
  journal = {Journal of Cancer Survivorship},
  year = {2026},
  volume = {20},
  number = {S2},
  pages = {1467--1478},
  doi = {10.1007/s11764-026-01976-9}
}
Kostenlos starten →